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Abstract 
Purpose: A systematic review and meta-analysis was conducted to answer the question ‘In adults with respiratory 
failure requiring invasive ventilation for more than 24 h, does a weaning strategy with early extubation to non-invasive 
ventilation (NIV) compared to invasive ventilation weaning reduce all-cause hospital mortality?’
Methods: We included randomised and quasi-randomised controlled trials that evaluated the use of non-invasive 
ventilation, compared to invasive ventilation, as a weaning strategy in adults mechanically ventilated for at least 24 h. 
The EMBASE, MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) bibliographic databases were 
searched from inception to February 2018. Bayesian hierarchical models were used to perform the meta-analysis. 
The primary outcome was mortality at hospital discharge. Secondary outcomes included mortality (30, 60, 90 and 
180 days), quality of life, duration of invasive ventilation, weaning failure, length of stay [intensive care unit (ICU) and 
hospital] and adverse events.
Results: Twenty-five relevant studies involving 1609 patients were included in the quantitative analysis. Studies 
had moderate to high risk of bias due to risk of performance and detection bias. Mortality at hospital discharge was 
lower in the NIV weaning group compared to the invasive weaning group [pooled odds ratio (OR) 0.58, 95% highest 
density interval (HDI) 0.29–0.89]. Subgroup analyses showed lower pooled mortality at hospital discharge rates in NIV 
weaning than those in the control group in chronic obstructive pulmonary disease (COPD) patients (pooled OR 0.43, 
95% HDI 0.13–0.81) and the effect is less certain in the mixed ICU population (pooled OR 0.88, 95% HDI 0.25–1.48). 
NIV weaning reduced the duration of invasive ventilation in patients [standardised mean difference (SMD) − 1.34, 
95% HDI − 1.92 to − 0.77] and ICU length of stay (SMD − 0.70, 95% HDI − 0.94 to − 0.46). Reported rates of ventilator 
associated pneumonia (VAP) were lower in the NIV group. NIV weaning did not reduce overall hospital length of stay 
or long-term mortality. There were insufficient data to compare other adverse events and health-related quality of life.
Conclusions: The use of NIV in weaning from mechanical ventilation decreases hospital mortality, the incidence of 
VAP and ICU length of stay. NIV as a weaning strategy appears to be most beneficial in patients with COPD.
*Correspondence:  j.yeung.4@warwick.ac.uk 
1 Warwick Clinical Trials Unit, Warwick Medical School, University 
of Warwick, Coventry, UK
Full author information is available at the end of the article
Systematic review registration: PROSPERO (CRD42017076522).
Introduction
Mechanical ventilation is used to treat 30–40% of patients 
admitted to critical care [1, 2]. Duration of invasive ven-
tilation is associated with increased mortality [2]. Suc-
cessful weaning and liberation from invasive mechanical 
ventilation is important to improve outcomes in critically 
ill patients [3]. Current international guidelines recom-
mend daily assessment of readiness for extubation with 
a spontaneous breathing trial, regular breaks in seda-
tion, early mobilisation and protocolised rehabilitation to 
help with weaning [4]. However, in common with many 
critical care interventions, successful liberation from 
ventilation is a complex process that requires patients 
to co-operate, breathe without mechanical aid, maintain 
their airway, expectorate secretions and tolerate ensuing 
physiological stress. The process of reliably identifying 
when a patient is ready to be extubated following invasive 
mechanical ventilation is clinically challenging [5]. Spon-
taneous breathing trials (SBT) are a commonly used test 
to assess patients’ readiness to wean [6, 7]. They assess 
the patients ability to breathe without positive airway 
pressure support. Most patients are successfully weaned 
off ventilation following the first SBT, but up to a third of 
patients fail one or more SBTs, requiring prolonged ven-
tilation and are deemed ‘difficult to wean’ [3, 8]. Whilst 
modern ventilators have improved with advancing tech-
nology, there is a lack of consensus of how best to con-
duct weaning in this population [5].
Non-invasive ventilation has become a commonly 
used alternative to invasive ventilation [9]. Extuba-
tion to non-invasive ventilation (NIV) following a failed 
SBT may be an attractive weaning strategy. The ben-
efits of this approach include avoidance of the injurious 
effects of invasive mechanical ventilation and reduction 
in sedation requirements and a lower risk of nosocomial 
pneumonia [3, 8]. The key risk is the potential need for 
re-intubation, which is associated with an increased risk 
of mortality [10]. Non-invasive ventilation could, how-
ever, prolong the period of weaning if it led to continu-
ation of non-invasive mechanical ventilation longer than 
would have occurred with an invasive ventilation wean-
ing strategy. Thus uncertainty exists about the most effec-
tive strategy. Current European Respiratory Society/
American Thoracic Society guidelines recommend that 
NIV be used as a weaning strategy from invasive venti-
lation, but this recommendation is limited to hypercap-
nic respiratory failure patients [11]. These guidelines are 
based on the 2014 Cochrane review on the use of non-
invasive weaning, which included 16 randomised studies 
and concluded that NIV weaning was superior to inva-
sive weaning with significantly reduced mortality, wean-
ing failures, ventilator associated pneumonia (VAP), 
intensive care and hospital length of stay and total dura-
tion of mechanical ventilation [12]. However, these stud-
ies were often conducted in single centres involving small 
number of patients, limiting the generalisability of their 
review findings.
On the basis of ongoing clinical uncertainty as to opti-
mum weaning strategy, the UK National Institute of 
Health Research commissioned the Breathe study in 
2013. As the largest randomised controlled trial pub-
lished to date which addresses this clinical question, the 
recent publication of the Breathe study provides a timely 
opportunity to review clinical evidence in this area [13]. 
The aim of this systematic review and meta-analysis is 
to evaluate the effect of a weaning strategy of using non-
invasive ventilation, compared with ongoing invasive 
mechanical ventilation, in adult patients that are consid-
ered clinically ready for weaning on mortality at hospital 
discharge and other clinically important outcomes.
Methods
We conducted this systematic review and meta-analysis 
in accordance with a protocol, registered with PROS-
PERO (CRD42017076522).
Study eligibility criteria
We included all randomised and quasi-randomised 
controlled trials that evaluated the use of non-invasive 
ventilation, compared to invasive ventilation, as a wean-
ing strategy in adults with respiratory failure intubated 
for at least 24 h. We excluded studies of weaning in the 
immediate (up to 24 h) postoperative period, or where a 
comparator group was either standard oxygen therapy or 
continuous positive airway pressure (CPAP). Quasi-ran-
domised controlled trials were defined as interventional 
trials where the group allocation was not truly random 
(e.g. group allocation by day of week). Studies of NIV 
use after unplanned extubation, as a rescue therapy after 
failed extubation, and to facilitate tracheostomy weaning 
were also excluded.
We included studies reported only as abstracts. No 
date or language restrictions were applied.
Information sources and search strategy
We searched EMBASE, MEDLINE and the Cochrane 
Central Register of Controlled Trials (CENTRAL) bib-
liographic databases (from inception to 2018) using a 
Keywords: Invasive mechanical ventilation, Non-invasive ventilation, Weaning, Systematic review, Bayes theorem
combination of keywords and MeSH terms in February 
2018. An example search strategy is included in the elec-
tronic supplementary material (ESM). Additional cita-
tions were identified through citation tracking (forward 
and backward) of eligible studies and relevant systematic 
review papers (see Supplementary Appendix A in ESM 
for search strategy).
On search completion and following duplicate removal, 
two authors (JY/KC) independently assessed the title of 
each citation and excluded obviously irrelevant titles. A 
third author (SG) acted as adjudicator where agreement 
could not be reached. Following title screening, the same 
independent review process was adopted for the screen-
ing of abstracts and full texts.
Data extraction
Data were extracted onto a piloted proforma by one 
author and checked for accuracy by a second author (JY/
KC). Extracted data included study characteristics (e.g. 
setting, publication year), population characteristics (e.g. 
proportion of patients with chronic pulmonary disease), 
characteristics of the intervention and comparator, and 
outcomes.
Outcomes
The primary review outcome was mortality at hospital 
discharge. Secondary outcomes were mortality (meas-
ured at 30, 60, 90 and 180  days), health-related quality 
of life, duration of invasive ventilation, weaning failure, 
intensive care unit (ICU) length of stay, hospital length of 
stay and adverse events.
We acknowledged that there would likely be variation 
in the definition of outcomes such as weaning failure, so 
elected to accept the outcome as defined in each study. 
For the adverse event of VAP, we excluded studies that 
reported non-specific pneumonia outcomes, such as 
nosocomial pneumonia or antibiotic use.
Risk of bias
We assessed risk of bias in individual studies using the 
Cochrane tool for bias assessment in randomised con-
trolled studies. The assessment was undertaken by two 
authors (JY/KC). We assessed effects of publication bias 
on primary outcome of mortality by constructing and 
visually inspecting a funnel plot of study effect estimates 
and standard error of log RR.
Synthesis of results
Bayesian hierarchical models were used to perform the 
random effects meta-analysis to account for between-
trial variations in treatment effects, as well as variabil-
ity within a trial. Bayesian hierarchical models allow for 
partial pooling of information across trials, and so the 
Bayesian estimate of the treatment effect for each trial 
is informed by the results of other trials. This improves 
estimates of treatment effects where there is little infor-
mation, and reduces the sensitivity of the estimates to 
studies with extreme results. We employed the Bayesian 
approach for its flexibility and ability to model a small 
number of studies and account for uncertainty in the 
treatment effect. Bayesian analyses allow previous infor-
mation about the treatment effect to be incorporated 
via the prior distribution. This is then updated using the 
current data to become the posterior distribution, which 
provides the probability of various estimates of the treat-
ment effect.
Posterior distributions were obtained for the treatment 
effect for each study and the posterior mean estimate 
and 95% highest posterior density interval (95% HDI) 
were used to summarise the Bayesian estimates. HDIs 
are Bayesian alternatives to confidence intervals and for 
a 95% HDI there is a 95% probability that the treatment 
effect falls in this interval. A posterior distribution for 
the treatment effect across the studies was also obtained 
from the Bayesian hierarchical model, where the mean 
represented the pooled effect and the variance of this dis-
tribution describes the between-study heterogeneity.
The Bayesian model requires specification of prior 
distributions for the pooled effect and between-study 
heterogeneity. We used minimally informative prior dis-
tributions for the meta-analysis since we incorporated 
all relevant previous studies into the meta-analysis and 
wanted the data from these trials to drive the final infer-
ences. A normal distribution with a large variance, N(0, 
 106), was used for the pooled treatment effect. A uniform 
distribution with a lower bound of 1/1000 was used for 
the between-study standard deviation to ensure positive 
values; an upper bound of 10 was generally used, apart 
from the 30-, 60- and 90-day mortality which used an 
upper bound of 2 due to convergence issues and the small 
number of studies.
For each outcome, we assumed that the treatment 
effect for each study was normally distributed and had 
its own mean and variance (assumed to be equal to the 
study’s observed variance). For binary outcomes (i.e. 
hospital mortality, 30-, 60- and 90-day mortality, VAP), 
we assumed that the logarithms of the odds ratios (OR) 
were normally distributed. Since most of the studies have 
a small sample size, and there are zero counts for some 
studies, a value of 0.5 was added to each of the cells (in 
the 2 × 2 table that the data formed for each study) so 
that the log OR could be calculated [14]. For the duration 
of invasive ventilation and length of stay (LOS; hospital 
and ICU LOS) outcomes, means and standard deviations 
from each of the studies were used in the meta-analysis. 
Studies that report medians and interquartile ranges 
were not included in the meta-analyses. Effect sizes for 
the duration/LOS outcomes were calculated as the stand-
ardised difference in the means (SMD), i.e. Hedges’ g 
[15], and were assumed to be normally distributed. The 
Bayesian hierarchical models did not include covariate 
adjustment.
The Bayesian meta-analyses were performed using 
the Markov chain Monte Carlo (MCMC) algorithm and 
were conducted in R (version 3.4.1) using the rjags pack-
age (JAGS version 4.3.0). Three chains were run using 
the MCMC algorithm, each with 50,000 iterations and 
a burn-in of 1000 iterations (and a thinning of 10). Con-
vergence of the chains was determined by examining the 
trace and density plots of the parameters, and the Gel-
man–Rubin diagnostic [16] (see Supplementary Appen-
dix B in in ESM for code and Appendix C for datasets).
Analysis of subgroups or subsets
We performed subgroup analysis for the majority of out-
comes to examine studies by patient population: chronic 
pulmonary disease (COPD) patients compared with the 
mixed ICU population. On the basis of a previous sys-
tematic review by Burns et  al., there might be signifi-
cantly higher mortality benefit for COPD patients in NIV 
weaning [17]. Clinical guidelines from Canadian Critical 
Care Trials Group/Canadian Critical Care Society Non-
invasive Ventilation Guidelines Group also suggested 
that NIV should be used to facilitate early liberation from 
mechanical ventilation in COPD patients but no recom-
mendation was made for the mixed ICU population due 
to lack of benefit [18]. We were unable to perform this 
subgroup analysis for 30-, 60- and 90-day mortality due 
to limited number of studies.
For the primary outcome, we also performed an addi-
tional subgroup analysis to examine studies by inter-
vention type: studies that used protocolised weaning 
compared with studies where a weaning protocol was not 
used (or not stated). We defined protocolised weaning as 
a strategy where, provided there was no contraindication, 
ventilatory support was reduced by a set amount (e.g. 
2 cmH2O) over a set time period (e.g. every 2 h).
We conducted two sensitivity analyses for the pri-
mary outcome, which were not defined a priori. Firstly, 
we repeated our meta-analysis with different priors to 
examine the impact of our choice of prior on the model 
and findings of our meta-analysis. We also examined the 
group of studies that used a failed SBT as a requirement 
for study entry as this reflects current standard practice.
Results
Database searches identified 1508 citations with a further 
nine citations identified through citation tracking (Fig. 1). 
Following removal of duplicates and ineligible citations, 
we included 25 relevant studies involving 1609 patients 
in the quantitative analysis. Characteristics of included 
studies are shown in Table  1. The majority of included 
studies were conducted in Asia (n = 11, 46%) and Europe 
(n = 8, 32%). Eighteen studies (72%) were reported as 
single-centre, with only three studies (12%) having more 
than five centres. Across all studies, the total sample size 
was 1609 with a median sample size per study of 50 (IQR 
30–69). Most studies recruited only patients with chronic 
respiratory disease (n = 15, 60%), although these studies 
accounted for only 49% (n = 783) of the total sample. The 
remaining ten studies (40%) recruited a mixed ICU pop-
ulation. None of the included studies reported outcome 
data adjusted for baseline patient characteristics.
Studies included patients that were considered poten-
tially suitable for extubation (e.g. acceptable level of 
consciousness, oxygen requirement and haemody-
namic status), although precise inclusion criteria varied 
between studies. Fourteen studies (56%) used a failed 
SBT as a trigger for study entry, which excluded patients 
who would be suitable for immediate extubation. Other 
studies used completion of the pulmonary infection con-
trol (PIC) window (20%) or a specified period of invasive 
mechanical ventilation. Only six studies described the 
use of a standardised weaning protocol whilst no details 
were provided in the other studies.
Risk of bias
The risk of bias across studies varied markedly (Fig.  2). 
There was a lack of description of randomisation in the 
majority of studies. The inability to blind caregivers to 
treatment allocation meant that all studies were consid-
ered to be at high risk of performance bias. The major-
ity of the included studies did not describe any strategies 
to blind outcome assessors from group allocation. Stud-
ies were rarely registered, creating a risk of selective 
reporting. Visual inspection of funnel plot did not reveal 
important asymmetry or publication bias for mortality 
outcome.
Outcomes
The primary outcome of hospital mortality was reported 
in 16 studies [13, 19–33], which included 1156 patients. 
Overall, hospital mortality was lower in the NIV weaning 
group compared to the invasive weaning group (pooled 
OR 0.58, 95% HDI 0.29–0.89) [27]. Subgroup analyses of 
studies by patient population showed that pooled hospi-
tal mortality rates were lower in the NIV arm than those 
in the control group in patients with COPD (pooled OR 
0.43, 95% HDI 0.13–0.81). In the mixed ICU popula-
tion, pooled hospital mortality rates were similar and 
there was no evidence of difference in survival observed 
between the two arms (pooled OR 0.88, 95% HDI 
0.25–1.48) but a wide HDI for this outcome made the 
results less clear-cut for this population (Fig. 3).
In a subgroup analysis on the primary outcome, we 
compared the results of studies which had a specified 
protocol for weaning and studies that did not specify a 
protocol for weaning. For the protocolised weaning stud-
ies, the pooled OR for hospital mortality was 0.59 (95% 
HDI 0.06, 1.25). For the studies that had no protocol for 
the weaning, the pooled OR for hospital mortality was 
0.60 (95% HDI 0.23, 1.01) (Fig. 4).
Other mortality outcomes were infrequently reported, 
such that meta-analyses included only three 30-day 
studies [13, 36, 37], three 60-day studies [34, 35, 39] and 
three 90-day studies [13, 19, 38]. In the meta-analyses, 
the pooled OR for 30-day, 60-day and 90-day mortality 
was lower in NIV group, but the 95% HDI crossed one 
for each of these analyses (Supplementary Fig. 5 in ESM). 
Only one study reported on survival at 180 days and did 
not find a survival benefit with NIV weaning [13].
Health-related quality of life was reported in only one 
study and was reported to be similar between NIV wean-
ing and invasive weaning patients [11].
Duration of invasive ventilation was reported to be 
reduced by NIV weaning in all 19 studies (1171 patients) 
[13, 19–24, 28–32, 34, 36–41]. Overall NIV weaning 
reduced the duration of invasive ventilation duration in 
patients (SMD − 1.34, 95% HDI − 1.92 to − 0.77). In the 
subgroup analysis, the duration of invasive ventilation 
was reduced in both COPD patients (SMD − 1.63, 95% 
HDI − 2.52 to − 0.80) and the mixed ICU population 
(SMD − 0.78, 95% HDI − 1.44 to − 0.08) (Supplementary 
Fig. 6 in ESM).
ICU and hospital LOS were reported in 17 (1094 
patients) [13, 19, 21–25, 28, 29, 31–33, 36–41] and 9 
(780 patients) [13, 19, 20, 22, 23, 30, 31, 38, 40] stud-
ies, respectively. One study could not be included in the 
meta-analysis for ICU LOS due to data discrepancies 
within the paper [42]. Overall NIV weaning reduced 
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Fig. 2 Risk of bias
LOS on ICU compared to invasive weaning (SMD − 0.70, 
95% HDI − 0.94 to − 0.46). In the subgroup analysis, all 
11 studies in COPD patients reported reduction in ICU 
LOS with the use of NIV weaning (SMD − 0.84 days, 95% 
HDI − 1.10 to − 0.56) (Supplementary Fig. 7 in ESM). Six 
studies reported reduced ICU LOS but the reduction was 
smaller (SMD − 0.47, 95% HDI − 0.98 to 0.03) and HDIs 
were wide in the mixed ICU population. There was also a 
reduction in hospital LOS overall (SMD − 0.76, 95% HDI 
− 1.60 to 0.03) which was less striking and the overall 
Fig. 3 Forest plot comparing hospital mortality rates for NIV and invasive weaning, by patient population (COPD vs. mixed ICU population). The 
estimated odds ratio (OR) from the posterior distribution for each study is shown as a circle, with 95% HDI represented by horizontal lines. The 
observed OR are given by crosses. The pooled OR estimates (and 95% HDI) are also displayed as the last row for each patient population, and the 
overall pooled estimate for all studies is displayed as the last row. An OR < 1 means that the intervention is superior
Fig. 4 Forest plot comparing hospital mortality rates for NIV and invasive weaning, by studies that used protocolised weaning and those that did 
not. The estimated odds ratio (OR) from the posterior distribution for each study is shown as a circle, with 95% HDI represented by horizontal lines. 
The observed OR are given by crosses. The pooled OR estimates (and 95% HDI) are also displayed as the last row for each patient population. An 
OR < 1 means that the intervention is superior
pooled estimates did not suggest a reduction in LOS in 
COPD or the mixed ICU population (Supplementary 
Fig. 8 in ESM).
Weaning failure was reported in 13 studies [13, 19, 24, 
27–29, 31, 33, 34, 37, 38, 41, 43]. Marked heterogeneity 
across studies in the way that weaning failure was defined 
precluded meta-analysis. The reported OR in 11 studies 
favoured non-invasive ventilation, although the 95% con-
fidence interval in nine of these studies transected one 
(Supplementary Fig. 9 in ESM).
For adverse events, we were able to compare VAP 
which was clearly defined and reported by 14 studies (722 
patients) [20–24, 28, 30, 31, 33–36, 41, 43]. Reported 
rates of VAP were lower in patients that received NIV 
weaning across all studies and pooled estimates sug-
gested that NIV lowered VAP rates in COPD and mixed 
ICU patients (Supplementary Fig.  10 in ESM). There 
were insufficient data to compare other reported adverse 
events.
Sensitivity analyses
For the majority of outcomes, there were little differ-
ences observed in the results of the meta-analyses from 
using different priors for the population standard devia-
tion or precision (Supplementary Table 2 in ESM). There 
were convergence issues in the MCMC algorithms when 
gamma priors were used for the population precision for 
the 30-, 60- and 90-day mortality, most likely due to the 
small number of studies for these measures. More precise 
priors were also explored for the population mean, but 
these had little impact on the results (results not shown).
A sensitivity analysis of hospital mortality using results 
from the nine studies (788 patients) that used a failed 
SBT as a requirement for study entry found there was no 
evidence that use of NIV weaning led to a difference in 
hospital mortality but the wide HDI precluded a defini-
tive statement of the effect on this outcome (pooled OR 
0.84, 95% HDI 0.31–1.37) (Supplementary Fig.  11 in 
ESM).
Discussion
This systematic review included 25 studies with 1609 
patients that compared NIV weaning to invasive wean-
ing in a randomised controlled trial. Our systematic 
review included the largest randomised controlled study 
conducted to date that addressed this research question. 
We were able to confirm that mortality at hospital dis-
charge was lower in the NIV weaning group compared 
to the invasive weaning group. In addition, NIV wean-
ing reduced both the duration of invasive ventilation and 
ICU LOS. To add to evidence in this area, our results 
also demonstrated that NIV led to substantially lower 
mortality at hospital discharge in patients with COPD 
but there was considerable uncertainty about the effects 
in the mixed ICU population. In addition, NIV weaning 
reduced both the duration of invasive ventilation and 
ICU LOS. In contrast to a previous systematic review, we 
did not find any difference in survival between patients 
that received protocolised versus non-protocolised wean-
ing [44].
Our results showed that NIV led to substantially lower 
hospital mortality in patients with COPD but there was 
considerable uncertainty about the effects in the mixed 
ICU population. Compared to patients without COPD, 
COPD patients are more prone to acute exacerbations 
and respiratory infections [45, 46]. Prolonged wean-
ing, prolonged mechanical ventilation and tracheotomy 
use are more common in patients with COPD and even 
more common in COPD patients with respiratory failure 
[47]. Since the most common reported causes of death 
in critically ill patients were refractory multi-organ fail-
ure and non-respiratory organ dysfunction, we suggest 
that the large survival effect seen in COPD patients may 
reflect the importance of reducing the duration of venti-
lation and lowering the risk of secondary complications 
in those with COPD [46, 48, 49]. It is also possible that 
the magnitude of the effect was magnified by the fact that 
studies that exclusively recruited COPD patients were 
mostly single-centred, involved fewer patients and were 
at increased risk of bias.
A potential limitation of previous reviews was the 
pooling of studies that used and did not use (or did not 
report the use of ) protocolised weaning strategies. This 
is important as the use of weaning protocols per se is 
associated with reduced duration of mechanical ventila-
tion and ICU LOS. In contrast to a previous systematic 
review, separate subgroup analysis examining proto-
colised versus non-protocolised weaning (or not stated) 
did not find additional survival benefit in patients who 
were weaning using a protocol [50]. However, descrip-
tion of protocol and their adherence were not always 
well described (Table  1). The point estimates for the 
odds ratio are similar for studies which used protocol-
ised weaning and those that did not. This finding suggests 
that the effects of non-invasive weaning are not limited to 
whether weaning protocols are used.
No long-term survival benefit of NIV was demon-
strated at 30, 60 or 90 days but firm conclusions could not 
be drawn from a limited number of studies. NIV weaning 
also reduced the duration of invasive ventilation and LOS 
in intensive care in COPD and the mixed ICU popula-
tions. Our findings are in agreement with contemporary 
literature in that the benefits of NIV weaning may stem 
from avoiding the injurious effects of prolonged invasive 
ventilation such as VAP, a complication that can often 
lengthen intensive care stay [51, 52]. It might also explain 
the survival benefit seen in COPD patients in whom such 
injurious effects may have the biggest impact. NIV has 
been used extensively to treat acute respiratory failure 
in patients with exacerbation of COPD. The beneficial 
effects of improved gas exchange reduce the work of res-
piratory muscles in respiratory failure and also facilitate 
resting of respiratory muscle, which may prove to be cru-
cial to patient outcomes in this cohort [53]. In contrast to 
the previous Cochrane review, our results did not find an 
overall reduction in hospital LOS. As a result of insuffi-
cient data, our review was unable to draw any inferences 
on the impact of NIV weaning on weaning failure and 
health-related quality of life.
Bayesian methods have previously been used to per-
form meta-analyses for clinical trials to overcome the 
limitations of traditional meta-analysis, such as account-
ing for missing data, a small number of studies, sparse 
event data, uncertainty in the unknown model param-
eters, incorporating external information and handling 
complex models (such as those which include covariates) 
[54, 55]. We employed the Bayesian approach for its flex-
ibility and ability to model a small number of studies and 
account for uncertainty in model parameters.
The main limitation of our systematic review is the 
variable quality of included studies. As most of the stud-
ies were not on a clinical trials register and did not have 
published protocols, it was not possible to assess report-
ing bias. There was often a lack of detailed description of 
the intervention and process of weaning and heterogene-
ity between studies in the patients included. Other valu-
able information such as sedation guidelines and weaning 
protocols were not available. Inconsistencies and varia-
tion in the reporting of adverse events precluded further 
analyses of other complications including weaning failure 
in the patient cohort. The need for core outcome sets in 
mechanical ventilation studies has been addressed by 
Core Outcomes in Ventilation Trials (COVenT) but the 
lack of consistent use of defined adverse events will con-
tinue to impact on the ability of future systematic reviews 
to reliably pool adverse event data [56, 57].
Despite evidence that critical care survivors can suf-
fer from poor physical and psychological outcomes and 
long-term impact on quality of life [58, 59], only one 
study reported on long-term outcomes [13]. The study 
did not find any significant difference in the patient-cen-
tred outcome of health-related quality of life at 90 and 
180 days but was not powered to do so [13]. Prevention 
of long-term sequelae and supporting patients post criti-
cal care discharge remains a challenge and it is important 
that future critical care research examines patient-cen-
tred long-term outcomes [60].
It remains difficult to combine the results of nine stud-
ies that used a pulmonary infective control (PIC) window 
instead of an SBT to determine whether the patients are 
ready to be extubated. The PIC window uses clinical signs 
to determine whether the patient has recovered from pul-
monary infection after receiving invasive ventilation and 
adequate antibiotics for 6–7 days. These include a signifi-
cant decrease in infectious infiltrations demonstrated by 
chest radiograph; significantly decreased quantity and 
viscosity of sputum; normal temperature and normalising 
of leukocyte count. Whilst popular in China, the ability 
to breathe spontaneously with reduced ventilator support 
is not tested and the clinical efficacy of the PIC window 
as an assessment of readiness to wean remains unproven 
[61]. Results from these studies may not be generalisable 
to intensive care populations in other countries.
Conclusions
Our review demonstrates that the use of NIV in wean-
ing from mechanical ventilation, compared with ongo-
ing invasive ventilation, reduces hospital mortality, the 
incidence of VAP and length of ICU stay, particularly in 
patients with COPD. On this basis, extubation to NIV 
may be a reasonable clinical strategy in patients that fail 
an SBT, particularly in patients with COPD.
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